Health Care [ 8/12 ] | Biotechnology [ 29/73 ]
NASDAQ | Common Stock
Immunic, Inc., a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany.
Its lead development program is IMU-838, which is in Phase 3 clinical and phase 2 clinical development for patients with relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.
The company also develops IMU-856, which is entering Phase 2 clinical trial, for the restoration of the intestinal barrier function in patients suffering from gastrointestinal diseases, such as celiac disease, inflammatory bowel disease, short bowel syndrome, irritable bowel syndrome with diarrhea, and other intestinal barrier function diseases; and IMU-381, which is in preclinical trial, for the treatment of gastrointestinal diseases.
Immunic, Inc. was founded in 2016 and is headquartered in New York, New York.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Jun 11, 25 | -0.25 Increased by +16.67% | -0.24 Decreased by -4.17% |
| Mar 20, 25 | -0.25 Increased by +47.92% | -0.24 Decreased by -6.07% |
| Nov 7, 24 | -0.24 Increased by +52.94% | -0.22 Decreased by -9.09% |
| Aug 8, 24 | -0.21 Increased by +61.11% | -0.23 Increased by +8.70% |
| May 8, 24 | -0.30 Increased by +48.28% | -0.26 Decreased by -15.38% |
| Feb 22, 24 | -0.48 Increased by +70.37% | -0.51 Increased by +5.88% |
| Nov 14, 23 | -0.51 Increased by +26.09% | -0.55 Increased by +7.27% |
| Aug 3, 23 | -0.54 Increased by +25.00% | -0.52 Decreased by -3.85% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Mar 31, 25 | 0.00 Decreased by N/A% | -25.47 M Increased by +13.90% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 24 | 0.00 Decreased by N/A% | -25.18 M Decreased by -16.70% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 24 | 0.00 Decreased by N/A% | -24.37 M Decreased by -7.02% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 24 | 0.00 Decreased by N/A% | -21.38 M Increased by +10.91% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 24 | 0.00 Decreased by N/A% | -29.58 M Decreased by -27.18% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 23 | 0.00 Decreased by N/A% | -21.57 M Increased by +75.65% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 23 | 0.00 Decreased by N/A% | -22.77 M Decreased by -1.96% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 23 | 0.00 Decreased by N/A% | -24.00 M Decreased by -9.58% | Decreased by N/A% Decreased by N/A% |